HOW TO EFFECTIVELY MANAGE TWO MAJOR DEFECTS IN TYPE 2 DIABETES MELLITUS?


如何引用文章

全文:

详细

The article considers the modern views on the pharmacotherapy of type 2 diabetes mellitus (DM2). The mechanisms of action of metformin and sulfonylureas from the standpoint of the pathogenesis of the disease are discussed. Particular attention is paid to the combined therapy of DM2. The results of comparative studies of efficacy and safety of fixed combinations of metformin with different sulfonylureas are presented. By the example of drug Amaryl-M, high efficacy of fixed combination (glimepiride + metformin) is shown, which is achieved due to the effect on two major pathogenetic defects in DM2. The potentials for use of this drug in patients of various categories are discussed.

参考

  1. Adeghate E, Schatiner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci 2006;1084(1):1-29.
  2. Kimmel B, Inzucchi EM. Oral Agents for Type 2 Diabetes. An Update. Clin Diabetes 2005;23(2):64-76.
  3. Nyenwe EA, Jerkins TW, Umpierrez GE, Ki AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metab Clin and Experim 2011;60:1-23.
  4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281(21):2005-12.
  5. Kahn SE. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003:46(1):3-19.
  6. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An Update. Ann Intern Med 2002;137:25-33.
  7. Schmitz O, Lund S, Andersen PH, et al. Optimizing insulin secretogogue therapy in patients with type 2 diabetes. Diabetes Care 2002;25:342-46.
  8. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metab Clin and Experim 2006;55(1):20-7.
  9. Aguilar-Bryan L, Nichols CG, Wechsler SF. Cloning of the β cell high affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-26.
  10. Campbell RK. Glimepiride role of new sulfonylureas in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-52.
  11. Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998;14(15):439-35.
  12. Tentolouris N, Matsagura M, Psallas M, et al. Relationship between antidiabetic treatment with QT dispersion during acute coronary syndromes in type 2 diabetes: comparison between patients receiving sulfonylureas and insulin. Exp Clin Endocrinol Diabetes 2005;113:298-301.
  13. Curtis Triplitt Improving Treatment Success rates for Type 2 diabetes: recommendations for a changing environment. Am J Manag Care 2010;16:195-200.
  14. Shimpi RD, Patil PH, Kuchake VG, et al. Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 Diabetes mellitus. Inter J PharmTech Research 2009;1(1):50-61.
  15. Charpentier G, Fleury FM, Kabir M. Diabet Med 2001;18:828-34.
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-й выпуск / Под ред. И.И. Дедова, М.В. Шестаковой. М., 2011.
  17. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003;26:1408-12.
  18. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clinical Therapeutics 2002;24(3):460-67.
  19. Gonzalez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Compl 2009;23:376-79.
  20. Shimpi RD, Patil PH, Kuchake VG, et al. Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 Diabetes mellitus. Inter J PharmTech Research 2009;1(1):50-61.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##